Michael John Nicholson

Dr. Michael John Nicholson

Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Mississippi, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
MNMichael John Nicholson
Michael John Nicholson
CMChristopher Manley
Christopher Manley
DADanish Ahmad
Danish Ahmad
Thoracentesis is a fundamental procedure in interventional pulmonology, providing both diagnostic and therapeutic value. This review article offers a comprehensive analysis of thoracentesis, delving into pleural anatomy, procedural techniques, indications, and recent advancements. The article details the evolution of thoracentesis, including the crucial role of ultrasound guidance and emerging approaches that enhance precision and minimize complications. It addresses the wide range of indications for thoracentesis in diverse clinical scenarios, from the diagnosis of pleural effusions to therapeutic drainage of pleural collections. Furthermore, this review explores the management of coagulopathy and anticoagulation pertaining to thoracentesis. It will also provide strategies for preventing and managing complications, ensuring that thoracentesis remains a well-tolerated procedure with minimal risks. This article concludes by examining future directions in thoracentesis, including potential innovations and trends that will shape the landscape of interventional pulmonary medicine. This review serves as an essential resource for pulmonologists, interventional radiologists, and healthcare professionals, offering a comprehensive update on thoracentesis.

7 September 2024 in JHLT Open
Verified
Journal Article
Open access
MNMichael John Nicholson
Michael John Nicholson
ZDZehra Dhanani
Zehra Dhanani
SGShameek Gayen
Shameek Gayen
Hypersensitivity pneumonitis is an interstitial lung disease that can progress to pulmonary hypertension which increases mortality. The European Society of Cardiology recently reduced the diagnostic criteria for precapillary pulmonary hypertension from mean pulmonary artery pressure ≥25mmHg to ≥20mmHg and pulmonary vascular resistance from ≥3Wu to ≥2Wu. We conducted a retrospective cohort study of the Scientific Registry of Transplant Recipients.1175 hypersensitivity pneumonitis patients listed for lung transplantation were divided into three groups based on the presence of precapillary pulmonary hypertension; those with pre-capillary pulmonary hypertension based on old criteria, new criteria, and those without precapillary pulmonary hypertension based on either criterion. The individual components of precapillary pulmonary hypertension were also assessed with three mean pulmonary artery pressure groups (≤20mmHg, >20mmHg to 2Wu to <3Wu, ≥3Wu). Survival analysis was performed. Kaplan-Meier analysis showed a difference in waitlist survival probability among the mean pulmonary artery pressure groups and among the pulmonary vascular resistance groups driven by the most severe groups. Multivariate Cox regression showed no difference between the various pre-capillary pulmonary hypertension groups. Pulmonary vascular resistance ≥3Wu was associated with increased waitlist mortality. The new thresholds of mean pulmonary artery pressure and pulmonary vascular resistance do not appear to prognosticate waitlist outcomes when combined. PVR ≥3Wu is associated with worse waitlist outcomes and may be useful in prognostication.

26 July 2024 in Journal of Pulmonology and Respiratory Research
Verified
Journal Article
Open access
PDF file
MNMichael John Nicholson
Michael John Nicholson
MSM Seigo
M Seigo
Alpha-1 antitrypsin deficiency is a genetic disorder that can lead to chronic obstructive pulmonary disease and emphysema. Although it is the most well-studied genetic risk factor for emphysema, data is still scarce. Traditionally, medical therapy is similar to standard chronic obstructive pulmonary disease patients. Over the past several decades, enzyme augmentation therapy has emerged as a highly utilized alpha-1 antitrypsin-specific therapy. It has become the standard of care for severe alpha-1 antitrypsin deficiency despite unclear effects on a multitude of clinical outcomes. Significant data supports interventional therapies, including lung volume reduction surgery and bronchoscopic lung volume reduction, for chronic obstructive pulmonary disease patients without alpha-1 antitrypsin deficiency. These interventions have less robust data in the treatment of alpha-1 antitrypsin-induced chronic obstructive pulmonary disease. This review will explore the data regarding various treatment options for severe alpha-1 antitrypsin deficiency associated with chronic obstructive pulmonary disease and emphysema.

1 July 2025 in Respiratory - The American Medical Journal
Verified
Journal Article
Open access
PDF file
MNMichael John Nicholson
Michael John Nicholson
IAIsam Albaba
Isam Albaba
OOOmar Al Omari
Omar Al Omari
GCGerard J Criner
Gerard J Criner
Bronchoscopic lung volume reduction (BLVR) with endobronchial valves has established effectiveness in improving lung function in patients...